[1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA A Cancer J Clin, 2021, 71(1): 7-33.
doi: 10.3322/caac.21654
|
[2] |
HAO M Z, ZHAO G, DU X L, et al. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in North China[J]. Tumour Biol, 2016, 37(8): 10339-10348.
doi: 10.1007/s13277-016-4914-4
|
[3] |
CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132.
doi: 10.3322/caac.21338
|
[4] |
SVEDMAN F C, PILLAS D, TAYLOR A, et al. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature[J]. Clin Epidemiol, 2016, 8: 109-122.
doi: 10.2147/CLEP.S99021
pmid: 27307765
|
[5] |
KIRKWOOD J M, IBRAHIM J G, SONDAK V K, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190[J]. J Clin Oncol, 2000, 18(12): 2444-2458.
doi: 10.1200/JCO.2000.18.12.2444
pmid: 10856105
|
[6] |
EGGERMONT A M, SUCIU S, MACKIE R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon Alfa 2b versus observation in patients with stage Ⅱb/Ⅲ melanoma (EORTC 18952): randomised controlled trial[J]. Lancet, 2005, 366(9492): 1189-1196.
doi: 10.1016/S0140-6736(05)67482-X
|
[7] |
CHAPMAN P B, HAUSCHILD A, ROBERT C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011, 364(26): 2507-2516.
doi: 10.1056/NEJMoa1103782
|
[8] |
EGGERMONT A M M, BLANK C U, MANDALA M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage Ⅲ melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial[J]. J Clin Oncol, 2020, 38(33): 3925-3936.
doi: 10.1200/JCO.20.02110
|
[9] |
DUMMER R, HAUSCHILD A, SANTINAMI M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage Ⅲ melanoma[J]. N Engl J Med, 2020, 383(12): 1139-1148.
doi: 10.1056/NEJMoa2005493
|
[10] |
DAVIES H, BIGNELL G R, COX C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892): 949-954.
doi: 10.1038/nature00766
|
[11] |
IKAWA S, FUKUI M, UEYAMA Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement[J]. Mol Cell Biol, 1988, 8(6): 2651-2654.
doi: 10.1128/mcb.8.6.2651-2654.1988
pmid: 3043188
|
[12] |
MAIO M, LEWIS K, DEMIDOV L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial[J]. Lancet Oncol, 2018, 19(4): 510-520.
doi: 10.1016/S1470-2045(18)30106-2
|
[13] |
FLAHERTY K T, INFANTE J R, DAUD A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations[J]. N Engl J Med, 2012, 367(18): 1694-1703.
doi: 10.1056/NEJMoa1210093
|
[14] |
BAI X, SHOUSHTARI A N, BETOF WARNER A, et al. Discrepancies in response and immune-related adverse events (IrAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)[J]. J Clin Oncol, 2021, 39(15_suppl): 9530.
doi: 10.1200/JCO.2021.39.15_suppl.9530
|
[15] |
LI T, JIA D D, TENG L S. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage Ⅲ melanoma: a retrospective cohort study[J]. Invest New Drugs, 2020, 38(5): 1334-1341.
doi: 10.1007/s10637-020-00913-6
|
[16] |
JIA D D, NIU Y L, ZHU H L, et al. Prior therapy with pegylated-interferon alfa-2b improves the efficacy of adjuvant pembrolizumab in resectable advanced melanoma[J]. Front Oncol, 2021, 11: 675873.
|
[17] |
GAO T F, LIU J, WU J. Cost-effectiveness analysis of dabrafenib plus trametinib and vemurafenib as first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in China[J]. Int J Environ Res Public Health, 2021, 18(12): 6194.
doi: 10.3390/ijerph18126194
|
[18] |
NAMIKAWA K, YAMAZAKI N. Targeted therapy and immunotherapy for melanoma in Japan[J]. Curr Treat Options Oncol, 2019, 20(1): 7.
doi: 10.1007/s11864-019-0607-8
|
[19] |
SI L, KONG Y, XU X W, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J]. Eur J Cancer, 2012, 48(1): 94-100.
|
[20] |
HAMID O, ROBERT C, DAUD A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J]. Ann Oncol, 2019, 30(4): 582-588.
doi: S0923-7534(19)31110-X
pmid: 31987275
|
[21] |
TOPALIAN S L, SZNOL M, MCDERMOTT D F, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol, 2014, 32(10): 1020-1030.
doi: 10.1200/JCO.2013.53.0105
pmid: 24590637
|
[22] |
SI L, ZHANG X S, SHU Y Q, et al. A phase ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)[J]. Transl Oncol, 2019, 12(6): 828-835.
doi: S1936-5233(18)30591-6
pmid: 30981094
|